Corbus Pharma (CRBP) Prices 6.67M Share Common Offering at $6/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures sink as AI doubts resurface, oil jumps
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 7, 2020 9:02 AM ESTNorwood, MA, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $6.00 per share, for a total public offering size of approximately $40 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of its common stock on the... More



